Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies
Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies
复制标题
DOI：
10.3324/haematol.2015.123562
复制
发表时间：
2015-08-01
期刊：
影响因子：
10.1
通讯作者：
Weitzman, Sheila
中科院分区：
文献类型：
--
作者：
Lehmberg, Kai;Nichols, Kim E.;Weitzman, Sheila
噬血细胞性淋巴组织细胞增生症可发生于恶性肿瘤。化疗期间，化疗引发的噬血细胞性淋巴组织细胞增生症应与噬血细胞性淋巴组织细胞增生症分开看待，后者通常与感染性触发因素相关。噬血细胞性淋巴组织细胞增生症的特征与肿瘤的特征之间的大量重叠使其在恶性情况下发生时难以识别。为了便于识别和诊断检查，并提供有关恶性相关噬血细胞性淋巴组织细胞增生症治疗的指导，由组织细胞学会噬血细胞性淋巴组织细胞增生症亚型研究组（一个由儿科和成人血液肿瘤学家和免疫学家组成的跨学科小组）制定了共识建议。
The hyperinflammatory syndrome hemophagocytic lymphohistiocytosis can occur in the context of malignancies. Malignancy-triggered hemophagocytic lymphohistiocytosis should be regarded seperately from hemophagocytic lymphohistiocytosis during chemotherapeutic treatment, which is frequently associated with an infectious trigger. The substantial overlap between the features of hemophagocytic lymphohistiocytosis with features of neoplasms makes its identification difficult when it occurs in malignant conditions. To facilitate recognition and diagnostic workup, and provide guidance regarding the treatment of malignancy-associated hemophagocytic lymphohistiocytosis, consensus recommendations were developed by the Study Group on Hemophagocytic Lymphohistiocytosis Subtypes of the Histiocyte Society, an interdisciplinary group consisting of pediatric and adult hemato-oncologists and immunologists.